Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir

Journal of Hepatology

Volumn 62, Issue 2, 2015, Pages 363-370

  Papatheodoridis, George V ^a   Dalekos, George N ^b   Yurdaydin, Cihan ^c   Buti, Maria ^d   Goulis, John ^e   Arends, Pauline ^f   Sypsa, Vana ^a   Manolakopoulos, Spilios ^a   Mangia, Giampaolo ^g   Gatselis, Nikolaos ^b   Keskin, Onur ^c   Savvidou, Savvoula ^e   Hansen, Bettina E ^f   Papaioannou, Christos ^a   Galanis, Kostantinos ^b   Idilman, Ramazan ^c   Colombo, Massimo ^g   Esteban, Rafael ^d   Janssen, Harry L A ^f,h   Lampertico, Pietro ^g  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c ANKARA UNIVERSITY   (Turkey)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF MILAN   (Italy)

^h TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Cirrhosis; CU HCC; Entecavir; GAG HCC; Hepatitis B; Hepatocellular carcinoma; REACH B; Risk scores; Tenofovir

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ALPHA INTERFERON; BILIRUBIN; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; GUANINE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; CU-HCC SCORE; DECOMPENSATED LIVER CIRRHOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ECHOGRAPHY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GAG-HCC SCORE; HEPATITIS B; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; PREDICTIVE VALUE; PRIORITY JOURNAL; REACH-B SCORE; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SENESCENCE; SEX DIFFERENCE; THROMBOCYTE COUNT; TREATMENT DURATION; VIRUS RESISTANCE; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; EPIDEMIOLOGY; ETHNOLOGY; GREECE; HEPATITIS B, CHRONIC; INCIDENCE; LIVER NEOPLASMS; MULTICENTER STUDY; NETHERLANDS; RISK FACTOR; SPAIN; TIME; TURKEY;

ADENINE; ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GREECE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NETHERLANDS; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SPAIN; TIME FACTORS; TURKEY;

EID: 84922226942     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.08.045     Document Type: Article

References (19)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
2. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. Lancet 2013; 381: 468-475.
3. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study. Hepatology 2011; 54: 91-100.
4. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing WF, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72.
5. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos( t)ide therapy: A systematic review. J Hepatol 2010; 53: 348-356.
6. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou- Gigi M, Vafiadis-Zoumbouli I, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: Results of the nationwide HEPNET. Greece cohort study. Gut 2011; 60: 1109-1116.
7. Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol 2013; 19: 8822-8830.
8. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 80-88.
9. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28: 1660-1665.
10. Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score. Lancet Oncol 2011; 12: 568-574.
11. Wong GL, Chan HL, Chan HY, Tse PC, Tse YK, Mak CW, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 2013; 144: 933-944.
12. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
13. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-352.
14. Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121-129.
15. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883-891.
16. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
17. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007; 12: 1295-1303.
18. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Longterm entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.
19. Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: A propensity score analysis. J Hepatol 2013; 58: 427-433.